SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-027404
Filing Date
2022-11-15
Accepted
2022-11-15 06:04:05
Documents
15
Period of Report
2022-11-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cbli20221114_8k.htm   iXBRL 8-K 33686
2 EXHIBIT 4.1 ex_447448.htm EX-4.1 34009
3 EXHIBIT 10.1 ex_447447.htm EX-10.1 35703
  Complete submission text file 0001437749-22-027404.txt   254589

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA stab-20221107.xsd EX-101.SCH 3602
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stab-20221107_def.xml EX-101.DEF 11533
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE stab-20221107_lab.xml EX-101.LAB 15415
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stab-20221107_pre.xml EX-101.PRE 11689
9 EXTRACTED XBRL INSTANCE DOCUMENT cbli20221114_8k_htm.xml XML 2567
Mailing Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526
Business Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526 (888) 613-8802
Statera Biopharma, Inc. (Filer) CIK: 0001318641 (see all company filings)

IRS No.: 200077155 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32954 | Film No.: 221389222
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences